Periera Carlton David, Warad Vijay, Rodrigues J P, Pandit Gayatri Subray, Gupte Vaishali, Thakur Gurmeet Kaur, Upadhyaya Ashish, Gogtay Jaideep
Department of ENT, Wadia Children Hospital Parel, Mumbai, Maharashtra, India.
Department of Pediatric Pulmonology, Sai Allergy Asthma Eye Children Hospital, Pune, Maharashtra, India.
J Asthma Allergy. 2025 Sep 4;18:1239-1251. doi: 10.2147/JAA.S516448. eCollection 2025.
Allergic rhinitis (AR) is a global health concern caused by allergen exposure. This Indian study utilized the Score for Allergic Rhinitis (SFAR) questionnaire to estimate the prevalence of AR among patients with nasal symptoms visiting doctors' clinics/hospitals.
This multicenter, cross-sectional study assessed AR using the SFAR questionnaire in patients with nasal symptoms visiting doctors' clinics/hospitals. It included patients aged ≥11 years across 19 states/union territories of India from September 2022 to April 2023. The score was digitally calculated using the Kribado device, with a score of ≥7 indicating the presence of AR. Patient-reported data covered demographics, seasonal patterns, symptoms, allergens/triggers, and prevalence. Associations among various risk factors were analyzed.
This study involved 3358 doctors, including ENT surgeons and chest physicians, and 40,001 patients across India. Among all patients, 53.7% (n=21,480) had SFAR scores ≥7. Sneezing was the most common symptom, reported by 69.1% of patients overall and 86.8% in the AR+ subgroup. House dust mites were the most prevalent allergens, affecting 73.8% of patients. Nose-related issues peaked from October to January. Half of the patients had a family history of asthma, eczema, or AR. In the AR+ subgroup, only 46% were diagnosed with allergies by a doctor, and 31.5% underwent allergy testing. After adjusting for variables, AR was significantly linked to nasal symptoms, including itchy and watery eyes, and a history of doctor-diagnosed allergies.
The in-clinic prevalence of AR in patients with nasal symptoms, as indicated by the SFAR questionnaire, is substantially high in India. A positive family history, indoor dust exposure, nasal symptoms, the months of October to January, and females were strongly linked to AR in Indian patients. The SFAR score is an effective in-clinic screening tool to support early AR diagnosis and management in India.
过敏性鼻炎(AR)是一种因接触过敏原而引发的全球性健康问题。这项印度研究使用过敏性鼻炎评分(SFAR)问卷来估计在前往医生诊所/医院就诊的有鼻部症状患者中AR的患病率。
这项多中心横断面研究在前往医生诊所/医院就诊的有鼻部症状患者中使用SFAR问卷评估AR。研究纳入了2022年9月至2023年4月期间印度19个邦/中央直辖区年龄≥11岁的患者。使用Kribado设备对分数进行数字化计算,分数≥7表明存在AR。患者报告的数据涵盖人口统计学、季节模式、症状、过敏原/触发因素以及患病率。分析了各种风险因素之间的关联。
这项研究涉及印度各地的3358名医生,包括耳鼻喉科外科医生和胸科医生,以及40001名患者。在所有患者中,53.7%(n = 21480)的SFAR分数≥7。打喷嚏是最常见的症状,总体上69.1%的患者报告有此症状,在AR阳性亚组中为86.8%。屋尘螨是最常见的过敏原,影响了73.8%的患者。与鼻子相关的问题在10月至1月达到高峰。一半的患者有哮喘、湿疹或AR的家族病史。在AR阳性亚组中,只有46%的患者被医生诊断为过敏,31.5%的患者接受了过敏检测。在对变量进行调整后,AR与包括眼睛瘙痒和流泪在内的鼻部症状以及医生诊断的过敏史显著相关。
根据SFAR问卷显示,在印度,有鼻部症状患者的门诊AR患病率相当高。家族史阳性、室内灰尘暴露、鼻部症状、10月至1月以及女性与印度患者的AR密切相关。SFAR分数是一种有效的门诊筛查工具,有助于在印度支持AR的早期诊断和管理。